BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 9274834)

  • 1. Beta2-Microglobulin dialysis amyloid and its formation: role of 3-deoxyglucosone and advanced glycation end products.
    Niwa T
    Nephron; 1997; 76(4):373-91. PubMed ID: 9274834
    [No Abstract]   [Full Text] [Related]  

  • 2. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum.
    Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y
    Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of dialysis-related amyloidosis.
    Miyata T; Maeda K
    Curr Opin Nephrol Hypertens; 1995 Nov; 4(6):493-7. PubMed ID: 8591057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis.
    Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y
    Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical localization of beta 2-microglobulin and advanced glycation end products in amyloid-enriched carpal tunnel ligament.
    Morita H; Shinzato T; Cai Z; Horiuchi S; Maeda K
    Nephron; 1996; 73(1):117-8. PubMed ID: 8742979
    [No Abstract]   [Full Text] [Related]  

  • 6. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure.
    Miyata T
    Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis.
    Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF
    Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-2 microglobulin in ESRD: an in-depth review.
    Winchester JF; Salsberg JA; Levin NW
    Adv Ren Replace Ther; 2003 Oct; 10(4):279-309. PubMed ID: 14681859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis.
    Miyata T; Sprague SM
    Nephrol Dial Transplant; 1996; 11 Suppl 3():86-90. PubMed ID: 8840320
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathophysiology of advanced glycation end-products in renal failure.
    Miyata T; Iida Y; Horie K; Cai Z; Sugiyama S; Maeda K
    Nephrol Dial Transplant; 1996; 11 Suppl 5():27-30. PubMed ID: 9044303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction.
    Miyata T; Maeda K
    Nephrol Dial Transplant; 1996; 11 Suppl 2():140-3. PubMed ID: 8804015
    [No Abstract]   [Full Text] [Related]  

  • 12. Alterations of synovial tissue and their potential role in the deposition of beta2-microglobulin-associated amyloid.
    Ehlerding G; Schaeffer J; Drommer W; Miyata T; Koch KM; Floege J
    Nephrol Dial Transplant; 1998 Jun; 13(6):1465-75. PubMed ID: 9641177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implication of the glycoxidation and lipoxidation reactions in the pathogenesis of dialysis-related amyloidosis (Review).
    Sugiyama S; Miyata T; Inagi R; Kurokawa K
    Int J Mol Med; 1998 Nov; 2(5):561-5. PubMed ID: 9858652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular heterogeneity of amyloid beta2-microglobulin and modification with advanced glycation end products.
    Mironova R; Niwa T
    J Chromatogr B Biomed Sci Appl; 2001 Jul; 758(1):109-15. PubMed ID: 11482729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis.
    Miyata T; Wada Y; Maeda K
    Contrib Nephrol; 1995; 112():52-64. PubMed ID: 7554993
    [No Abstract]   [Full Text] [Related]  

  • 16. Advanced glycation end products are associated with beta 2-microglobulin amyloidosis.
    Miyazaki S; Niwa T; Morita T; Koda Y; Yuasa Y; Sakai S; Suzuki M; Takahashi S; Hirasawa Y
    Am J Nephrol; 1995; 15(6):535-6. PubMed ID: 8546180
    [No Abstract]   [Full Text] [Related]  

  • 17. Amyloid, advanced glycation end products, and dialysis related arthropathy.
    McDonald SP; Coates PT; Disney AP
    Ann Rheum Dis; 1998 Apr; 57(4):193-5. PubMed ID: 9709172
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis.
    Miyata T; Inagi R; Kurokawa K
    Miner Electrolyte Metab; 1999; 25(1-2):114-7. PubMed ID: 10207272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced glycation end product-modified beta2-microglobulin is a component of amyloid fibrils of primary localized cutaneous nodular amyloidosis.
    Fujimoto N; Yajima M; Ohnishi Y; Tajima S; Ishibashi A; Hata Y; Enomoto U; Konohana I; Wachi H; Seyama Y
    J Invest Dermatol; 2002 Mar; 118(3):479-84. PubMed ID: 11874487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beta2-microglobulin and amyloidosis.
    Drüeke TB
    Nephrol Dial Transplant; 2000; 15 Suppl 1():17-24. PubMed ID: 10737162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.